PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go:
Extended
investment:
£295,000
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go:
Extended
investment:
Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go:
TBC
investment:
£127,001
Plerith works with high growth start-ups and scaling companies to plan for and deliver growth. The company asserts that it helps companies promote their business to potential funders, through its network of angel and venture capital investors depending on the stage and sector of the said business. Plerith is partnering with Newable and Bristol Private Equity Club to deliver the fund in the South West London (SWL) area and identify and invest in the most exciting high growth companies in the region. Plerith argues that its deep knowledge of fundraising, sales, strategy, finance and technology would help SWL businesses flourish. Plerith aims to provide investors access to the highest quality local companies in the SWL region.
days to go:
Stretch
investment:
Withheld
A car-sharing platform for drivers to receive an extra income by allowing the local community to drive their cars instead of leaving it idle and unused. Hiyacar has a acquired an exclusive insurance product with AXA and already has more than 2,000 cars enrolled, with the majority located in London and surrounding urban areas with the intention of expanding further in the future.
days to go:
Expired
investment:
£1,431,885
Qure are an affordable and convenient on-demand healthcare service providing a doctor to users doors within 2 hours, 24/7. The hassle-free healthcare connects individuals with highly-experienced medical practitioners in the local area.
days to go:
Expired
investment:
£720,000
FinOptix is an innovative FinTech company that solves real business problems. FinOptix’s objective is to become a significant player in a rapidly growing FinTech market by developing systems that provide financial clarity to decision-makers. FinOptix has a well-established user base, as well as a sales pipeline that covers multiple geographies and sectors. Their verification and validation procedures applied during the development process and operational trials have led to engagement with commercial partners. With the proceeds, they will design an Evaluator for the future, apply AI techniques to solve complex problems, develop their skill set and framework and hire a team of data scientists based on the assessment.
days to go:
Expired
investment:
£125,000
Over the past 8 years, Advatech Healthcare has created Hippo, a proven disabled and non-emergency patients transportation services (NEPTS) in the Essex area. Due to its dependability and efficiency, Hippo is now poised to become the UK's best national wheelchair accessible healthcare services on a wearable technology platform. According to the Office for Technology Statistics data, there are 13.37 million people disabled in the UK who lack dedicated non-emergency transportation. Hippo could save the National Health Service (NHS) up to 60% on transportation costs increasing faster hospital bed rotation and providing dedicated transportation for disabled and non-emergency patients with a medically trained staff. It also offers medical and technological necessities not offered by many leading operators. Currently, the company operates within the Essex area. By the end of 2020, the company aims to commence seven new contracts it has signed with the NHS. It also signed a deal with Cambridge Adult Social Care that is expected to close, within a 5-year term and generate over £200,000 per year.
days to go:
Expired
investment:
Withheld
Liquid supplements are a faster acting and a more efficient way for the body to absorb key active ingredients than taking pills. Our scientists have developed formulations involving leading active ingredients such as collagen in order to create the perfect wellness solution in every bottle. Each LQ bottle is packed full of 9 or more active ingredients all in one easy to drink, daily 50 m bottle.
days to go:
Expired
investment:
£355,000
The SidebySide Partnership is a London based Enterprise Investment Scheme (EIS) Venture Capital (VC) firm. Its purpose is to finance and control the management teams of its investee companies enabling them to become a developed corporate entity. The SidebySide Partnership's focus is on fast-growing technology businesses with £1 - 10 million in revenue. It provides 100% EIS relief on investment with zero initial/ongoing fees charged to investors. The SidebySide Partnership's investment experience of 20+ corporate acquisitions totalling more than $200 million, 20+ private investments, and a rate of interest of 12x over the last 35 years has enabled it to become a dependable platform for upcoming tech businesses. It will use the investment to grow its business across different verticals.
days to go:
Expired
investment:
£1,500,000
